In attendance:
Richard Frank, MD, PhD (Chair)  Matthew Miller, PhD
Michael Casey, PhD  Yuanxin Rong, MD, MPH
Paul Christian  Barry Siegel, MD
Patricia Cole, PhD, MD  Jeffrey Yap, PhD
Constantine Gatsonis, MD  Brian Zimmerman, PhD
Igor Grachev, MD, PhD  RSNA
John Hoffman, MD
Lisa Karam, PhD  Fiona Miller
Paul Kinahan, PhD  Susan Anderson
Steve Kohlmyer  Joe Koudelik

Role of the monthly Technical Committee (TC) calls (Dr. Frank)
- Coordination and problem solving
- Catch-up on and assess on subcommittees’ progress
- Prep for March 2009 Imaging Biomarkers Roundtable and May 2009 QIBA meeting

Participation on FDG-PET/CT Subcommittees
- RSNA staff to post a list of subcommittees with mission statements and Chair contact information on the QIBA Wiki
- RSNA staff to send “letter-of-interest” to TC group to encourage participation on subcommittees
- RSNA staff will provide administrative support and coordinate calls for all subcommittees

Leverage Pharmaceutical Industry and Vendor Participation
- Drs. Helen Young and Sandy McEwan (TC Co-chairs) to provide their fields’ perspective on value of QIBA FDG-PET/CT projects
- To provide value to the pharmaceutical industry and vendors, FDG-PET/CT co-chairs will review each subcommittee’s efforts and priorities
- Prioritization of resource needs across all six subcommittees is critical
- Important to engage pharmaceutical industry and vendors
- Engagement and buy-in from either industry may be used to leverage buy-in from the other
- Dr. Kinahan proposed inviting the 3rd party vendors identified in his recent information-gathering to join QIBA
  - E-mail to go out under Dr. Frank (FDG-PET TC Chair) and Dr. Kinahan (Subcommittee Chair) signatures to solicit vendor participation
  - Letter to list mission statement and reason for the invitation (introduction)
    - Dr. Kinahan will draft a letter and forward to RSNA staff
- Dr. Frank reminded all participants of the importance of transparency in communicating and including various stakeholders

Importance of Standardizing Protocols
- Must demonstrate value of QIBA activities to stakeholders
• Accurate, reproducible quantitative assessments across vendor platforms needed for FDA approval in drug development process
• Discussion at a recent SNM meeting dealt with the issue of protocol deviation
  o 30% of studies lost due to protocol deviation
  o Protocol deviations and missing endpoints mean losing the value and resources spent in enrolling patients in trials
• Standardization and control needed to increase efficiency and reduce funding inefficiencies
  o Working with the QIBA groups was proposed and encouraged
  o Drs. Mozley and Cole continue to interface with the pharmaceutical industry

Slide Decks from each Subcommittee
Different stakeholders require tailored slide decks stating specific benefits
• Slide decks must work for industry management
  o Group objectives/mission
  o Deliverables
  o Impact
  o Resources/Funding
  o Timelines
• A single (standard) slide deck needed also to present to stakeholders
  o Clearly stated objectives
  o Strategies
  o Specific tasks planned
  o Resources needed

Need to Leverage Interest from the Pharmaceutical Industry
• Vendors need to know the pharmaceutical industry wants this and may be willing to provide resources
• Vendors will buy-in by directing resources into research and clinical trials
• Vendor buy-in is needed for these trials and the overall good of all stakeholders

Economic Stimulus funding
• Stimulus funding may provide resources
• NIH will have money for change grants which will provide 2 years’ funding
• Can QIBA FDG-PET/CT take advantage of grants
  o Tech assessment initiative suggested, similar to AAPM effort
  o Should QIBA champion for NIH funding?
  o Should this extend beyond two years’ time frame?
  o Drs. Sullivan and Bresolin to discuss further

Next Steps:
• Prioritize projects within and across subcommittees
• Each subcommittee Chair is to assemble an overview slide deck and submit to (jkoudelik@rsna.org) by Friday, March 6th, 2009
• Slide deck should include the following:
  o Clearly stated objectives
  o Progress and details (current status)
  o Next steps (specific tasks planned)
  o Resources needed to deliver results
• RSNA staff will e-mail reminder to each subcommittee chair about slide deck
• RSNA staff to send out a letter-of-interest to all FDG-PET/CT TC members inviting their participation in one or more of the six subcommittees
• Letter to include mission statement, chair contact information, and current subcommittee roster
  Dr. Paul Kinahan and Paul Christian to join Dr. Yap’s Quality Control Metrics subcommittee
• Dr. Patricia Cole to join Dr. Turkington’s ROI Definitions subcommittee